PLA-PEG nanospheres decorated with phage display selected peptides as biomarkers for detection of human colorectal adenocarcinoma

Souza, Aline de; Castro-Borges, William; Andrade, Milton Hércules Guerra de; Maia, Yara Cristina de Paiva; Goulart, Luíz Ricardo; Lanna, Elisa Gomes; Brito, Ana Carolina Ferreira de; Barboza, Ana Paula Moreira; Mosqueira, Vanessa Carla Furtado; Rubio, Karina Taciana Santos

doi:10.1007/s13346-020-00826-0

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, P1, P2, BNP1 and BNP2 presented spherical or oval shapes, which corroborates the SEM results. In terms of particle size, the AFM images revealed smaller nanoparticles (200–300 nm) when compared to the DLS results, which can be explained by the dehydration of the nanoparticles submitted for AFM imaging [ 59 ].…”

Section: Resultsmentioning

confidence: 99%

Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease

Sousa,

Duarte,

Xavier

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Chagas disease (CD) is a worldwide public health problem. Benznidazole (BZ) is the drug used to treat it. However, in its commercial formulation, it has significant side effects and is less effective in the chronic phase of the infection. The development of particulate systems containing BZ is therefore being promoted. The objective of this investigation was to develop polymeric nanoparticles loaded with BZ and examine their trypanocidal impact in vitro. Two formulas (BNP1 and BNP2) were produced through double emulsification and freeze drying. Subsequent to physicochemical and morphological assessment, both formulations exhibited adequate yield, average particle diameter, and zeta potential for oral administration. Cell viability was assessed in H9C2 and RAW 264.7 cells in vitro, revealing no cytotoxicity in cardiomyocytes or detrimental effects in macrophages at specific concentrations. BNP1 and BNP2 enhanced the effect of BZ within 48 h using a treatment of 3.90 μg/mL. The formulations notably improved NO reduction, particularly BNP2. The findings imply that the compositions are suitable for preclinical research, underscoring their potential as substitutes for treating CD. This study aids the quest for new BZ formulations, which are essential in light of the disregard for the treatment of CD and the unfavorable effects associated with its commercial product.

show abstract

Section: Resultsmentioning

confidence: 99%